Omics-based discovery and characterization of bioactive natural products
A cutting-edge approach leveraging genomics and metabolomics to discover and enhance the production of novel bioactive compounds. This solution utilizes advanced bioassay-guided isolation and strain engineering to unlock microbial natural product potential.
Overview
Our innovative solution leverages omics technologies, including genomics and metabolomics, to discover and enhance the production of novel bioactive natural products. By mining whole genome sequences and predicting biosynthetic gene clusters (BGCs), we apply targeted metabolomic tools to assess and validate the biological activity of predicted metabolites. This approach is designed to overcome the limitations of traditional culture-based methods, enabling the discovery of novel compounds with significant bioactivity.
Technical specifications
- Genome Mining: Identification of candidate pathways using whole genome sequence data.
- Metabolite Production: Validation through differential production conditions and purification using bioassay-guided isolation.
- Strain Engineering: Enhancement of metabolite production via engineering wild-type strains or heterologous expression in optimized hosts.
- Analytical Methods: Utilizes LC-HRMS, LCMS, and NMR for structure elucidation and activity confirmation.
- Bioactivity Testing: High-throughput screening against phytopathogens and human pathogens.
Technology readiness level
This technology is currently at TRL 4, indicating that it has been validated in a laboratory setting. Further development will focus on optimizing production conditions and scaling up to bioreactor levels for commercial application.
About Fundación MEDINA
Fundación MEDINA is a non-profit research center in Granada’s Health Technology Park, built around an end‑to‑end natural‑products discovery platform and a seasoned pharma‑to‑foundation culture. Created through a public–private alliance with Merck Sharp & Dohme, the regional government, and the University of Granada, MEDINA partners via collaborations and fee‑for‑service programs that provide access to proprietary microbial collections, extract libraries, HTS, and advanced analytics. Its research‑park location places teams alongside university and hospital partners, easing compliance and talent pipelines. Activities are backed by competitive regional, national, and European funding. Business development and IP management support tailored agreements, material transfer, and licensing.
delivered to your inbox.